The burgeoning market for peptides, particularly those used in weight loss and anti-aging treatments, faces a critical juncture with an upcoming decision from the Food and Drug Administration (FDA). The industry, estimated to be worth $2.2 billion, has rapidly expanded through telehealth platforms, compounding pharmacies, and startups, often utilizing unapproved or compounded formulations.
The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet in late July to consider approving seven unapproved peptides for use in compounding pharmacies. A subsequent hearing is planned for early next year to review additional compounds. This review process could significantly impact the future growth and legitimacy of the peptide market.
Much of the current surge in peptide use has been driven by demand that traditional drug development has not yet met. Companies argue they are fulfilling consumer needs, while operating in what is often described as a regulatory gray zone. The proliferation of various peptides, including those marketed for longevity, has put the industry on a path toward potential regulatory scrutiny.
Companies are actively positioning themselves to capitalize on this expanding market. In February 2025, Hims & Hers acquired a peptide compounding facility, and Noom later purchased Tailor Made Compounding, which has operations in 46 states. Other companies, such as Mino, are linking clinicians and doctors with peptide suppliers and acquiring facilities. Telehealth startup Protocole, founded in 2025, raised $6 million in April and emphasizes its avoidance of "research use only" products.
However, some health boards are issuing warnings. In May, the Alabama Board of Medical Examiners cautioned physicians against recommending, supplying, prescribing, or administering these substances, citing a rise in unapproved peptides appearing in audits and patient complaints. Wilson Hunter, the board's general counsel, stated that the warning aimed to prevent harm from unvetted products.
The U.S. Department of Health and Human Services has indicated that public interest and black market use do not alter the FDA's scientific or regulatory standards, emphasizing the agency's ongoing review process. Regulatory experts note that compounding pharmacies producing some of these peptides are doing so without explicit FDA approval, and the agency is working to balance consumer demand with safety concerns in a rapidly evolving market.